StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM
Mizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Citi
December 7, 2021 5:22 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
December 7, 2021 5:15 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Morgan Stanley
December 7, 2021 2:39 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $39 at JMP Securities
December 7, 2021 2:02 AM
After-Hours Stock Movers 12/06: (ACAD) (MDB) (DWAC) Higher; (HQY) (OWL) (SI) Lower (more...)
December 6, 2021 5:27 PM
Form 8-K ACADIA PHARMACEUTICALS For: Dec 06
December 6, 2021 5:17 PM
Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
December 6, 2021 4:07 PM
